Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about JAZZ, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-04-16 | oral cannabidiol capsule formulation | NDA | 66% | ±21% by Jun 17 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cannabidiol FDA approved Jun 2018 · Epidiolex |
Lennox Gastaut Syndrome | Phase 4 · NCT05044819 | Active not recruiting |
| Lurbinectedin FDA approved Jun 2020 · Zepzelca |
Small-Cell Lung Cancer | Phase 3 · NCT05091567 | Active not recruiting |
| Zanidatamab (ZW25) FDA approved Nov 2024 · Ziihera |
Gastric Neoplasms | Phase 3 · NCT05152147 | Active not recruiting |
| Asparaginase Erwinia chrysanthemi FDA approved Jun 2021 · Rylaze |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 · NCT06738368 | Suspended |
| Defibrotide FDA approved Mar 2016 · Defitelio |
Covid19 | Phase 2 · NCT04652115 | Recruiting |
| JZP258 (XYWAV) | Idiopathic Hypersomnia | Phase 4 · NCT05875974 | Completed |
| Dordaviprone (ONC201) | Diffuse Intrinsic Pontine Glioma | Phase 3 · NCT05476939 | Recruiting |
| JZP926 capsule | Juvenile Myoclonic Epilepsy | Phase 2/3 · NCT07723963 | Recruiting |
| Fluorouracil | Gastric Neoplasms | Phase 3 · NCT05152147 | Active not recruiting |
| CBD-OS | Developmental and Epileptic Encephalopathy (DEE) | Phase 3 · NCT07723976 | Recruiting |
| Calcium, Magnesium, Potassium, And Sodium… | Narcolepsy | Phase 3 · NCT07625280 | Recruiting |
| DRD2 Antagonist/ClpP Agonist ONC206 | Meningioma | Phase 2 · NCT07533942 | Recruiting |
| Osimertinib | Small Cell Lung Cancer ( SCLC ) | Phase 1/2 · NCT07153055 | Recruiting |
| MicroRNA-10b Antagomir-Iron Oxide/Dextran-based… | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
| Vincristine | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 · NCT06738368 | Suspended |
| Evorpacept (ALX148) | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
Also used in these trials (approved or third-party drugs, not JAZZ's own candidates): Oxaliplatin, Gemcitabine Hydrochloride, Pembrolizumab, Everolimus, Etoposide, Durvalumab, Tislelizumab, Trastuzumab, Cisplatin, Carboplatin, Capecitabine, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
JAZZ holds $2.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JAZZ files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 6,454,463 | 10.06% | 2026-09-30 |
| FMR LLC | Institution (13G, 5%+) | 5,601,907 | 8.73% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,103,522 | 4.83% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 3,071,767 | 4.79% | 2026-09-30 |
| Capital World Investors | Institution (13F) | 2,393,393 | 3.73% | 2026-09-30 |
| LSV Asset Management | Institution (13F) | 2,135,935 | 3.33% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 2,067,988 | 3.22% | 2026-09-30 |
| Franklin Resources, Inc. | Institution (13F) | 1,943,969 | 3.03% | 2026-09-30 |
| Franklin Templeton, Inc. | Institution (13F) | 1,943,969 | 3.03% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,532,561 | 2.39% | 2026-09-30 |
| Dimensional Fund Advisors LP | Institution (13F) | 1,453,265 | 2.26% | 2026-09-30 |
| Seamus Mulligan Director |
Insider | 1,286,254 | 2.00% | 2026-08-05 |
Share count 64,189,052 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-06 filed 2026-11-10 |
COZADD BRUCE C |
Option exercise (M) | 734 | $136.18 | 340,609 |
| 2026-11-06 filed 2026-11-10 |
COZADD BRUCE C |
Option exercise (M) | 85,766 | $136.18 | 426,375 |
| 2026-11-06 filed 2026-11-10 |
COZADD BRUCE C |
Sale (S) | 27,714 | $234.91 | 398,661 |
| 2026-11-06 filed 2026-11-10 |
COZADD BRUCE C |
Sale (S) | 10,688 | $235.82 | 387,973 |
| 2026-11-06 filed 2026-11-10 |
COZADD BRUCE C |
Sale (S) | 24,483 | $236.84 | 363,490 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-08-25 | Ziihera | sBLA | +0.2% | +2.3% | — |
| 2025-11-05 | — | NDA | +0.2% | -0.4% | -0.5% |
| 2025-10-07 | — | NDA | +6.2% | -0.2% | -1.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAZZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →